These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38560142)

  • 1. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer.
    Schipilliti FM; Drittone D; Mazzuca F; La Forgia D; Guven DC; Rizzo A
    Heliyon; 2024 Apr; 10(7):e28385. PubMed ID: 38560142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
    Dent RA; Cescon DW; Bachelot T; Jung KH; Shao ZM; Saji S; Traina TA; Vukovic P; Mapiye D; Maxwell MJ; Schmid P; Cortés J
    Future Oncol; 2023 Nov; 19(35):2349-2359. PubMed ID: 37526149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
    Bardia A; Pusztai L; Albain K; Ciruelos EM; Im SA; Hershman D; Kalinsky K; Isaacs C; Loirat D; Testa L; Tokunaga E; Wu J; Dry H; Barlow W; Kozarski R; Maxwell M; Harbeck N; Sharma P
    Ther Adv Med Oncol; 2024; 16():17588359241248336. PubMed ID: 38686016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
    Bardia A; Jhaveri K; Kalinsky K; Pernas S; Tsurutani J; Xu B; Hamilton E; Im SA; Nowecki Z; Sohn J; Laurentiis M; Jañez NM; Adamo B; Lee KS; Jung KH; Rubovszky G; Tseng LM; Lu YS; Yuan Y; Maxwell MJ; Haddad V; Khan SS; Rugo HS; Pistilli B
    Future Oncol; 2024 Mar; 20(8):423-436. PubMed ID: 37387213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles.
    Fenton MA; Tarantino P; Graff SL
    Curr Oncol; 2023 Nov; 30(12):10211-10223. PubMed ID: 38132377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis.
    Gadaleta-Caldarola G; Lanotte L; Infusino S; Gadaleta-Caldarola A; Schipilliti FM; Citrigno C; Petrarota C; Cusmai A; Rizzo A
    Cancer Treat Res Commun; 2023; 37():100775. PubMed ID: 37956525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
    Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
    Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
    McNamara B; Greenman M; Bellone S; Santin LA; Demirkiran C; Mutlu L; Hartwich TMP; Yang-Hartwich Y; Ratner E; Schwartz PE; Santin AD
    Gynecol Oncol; 2024 Oct; 189():16-23. PubMed ID: 38981151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
    Okajima D; Yasuda S; Maejima T; Karibe T; Sakurai K; Aida T; Toki T; Yamaguchi J; Kitamura M; Kamei R; Fujitani T; Honda T; Shibutani T; Muramatsu S; Nakada T; Goto R; Takahashi S; Yamaguchi M; Hamada H; Noguchi Y; Murakami M; Abe Y; Agatsuma T
    Mol Cancer Ther; 2021 Dec; 20(12):2329-2340. PubMed ID: 34413126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
    Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J
    Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-Drug Conjugates in Triple Negative Breast Cancer.
    Keskinkilic M; Sacks R
    Clin Breast Cancer; 2024 Apr; 24(3):163-174. PubMed ID: 38341370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?
    Zardavas D
    Expert Opin Investig Drugs; 2022 Jun; 31(6):633-644. PubMed ID: 35451891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan.
    McGuinness JE; Kalinsky K
    Expert Opin Biol Ther; 2021 Jul; 21(7):903-913. PubMed ID: 33089726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs.
    Tang Q; Li H; Zhao XT; Li ZY; Ma CX; Zhou SQ; Chen D
    World J Oncol; 2024 Aug; 15(4):527-542. PubMed ID: 38993251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
    Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
    Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 18. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.
    Bardia A; Jhaveri K; Im SA; Pernas S; De Laurentiis M; Wang S; Martínez Jañez N; Borges G; Cescon DW; Hattori M; Lu YS; Hamilton E; Zhang Q; Tsurutani J; Kalinsky K; Rubini Liedke PE; Xu L; Fairhurst RM; Khan S; Denduluri N; Rugo HS; Xu B; Pistilli B;
    J Clin Oncol; 2024 Sep; ():JCO2400920. PubMed ID: 39265124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates.
    Jabbarzadeh Kaboli P; Shabani S; Sharma S; Partovi Nasr M; Yamaguchi H; Hung MC
    Am J Cancer Res; 2022; 12(4):1671-1685. PubMed ID: 35530278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel antibody-drug conjugates for triple negative breast cancer.
    Nagayama A; Vidula N; Ellisen L; Bardia A
    Ther Adv Med Oncol; 2020; 12():1758835920915980. PubMed ID: 32426047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.